mRNA vaccines developed against the spike glycoprotein of severe acute respiratory syndrome type 2 coronavirus (SARS-CoV-2), displayed remarkable efficiency in combating coronavirus 19 (COVID-19).
Mar 9 2024Tokyo University of Science mRNA vaccines developed against the spike glycoprotein of severe acute respiratory syndrome type 2 coronavirus , displayed remarkable efficiency in combating coronavirus 19 . These vaccines work by triggering both cellular and humoral immune responses against the spike protein of the virus.
To bridge this gap, a team of researchers, led by Associate Professor Satoshi Ueha, including Professor Kouji Matsushima from the Tokyo University of Science , Japan, Mr. Hiroyasu Aoki from the University of Tokyo, and Professor Toshihiro Ito from Nara Medical University, aimed to develop a kinetic profile of spike-reactive T-cell clones during repetitive mRNA vaccination.
By longitudinally tracking the total frequency of each response pattern, it was observed that, after the second shot, a shift among the clonotypes occurred, wherein the major population changed from early responders to main responders, suggestive of a shift in clonal dominance. A similar shift of responding clones was also observed in CD4+ T cells.
Due to the vaccination-induced shift in immunodominance of spike epitopes, the study supports the inter-epitope shift model. In addition, there were intra-epitope shifts of vaccine-responding clonotypes within spike epitopes.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study Estimates Fatigue Incidence and Predictors after SARS-CoV-2 InfectionScientists at the CDC and Washington University have conducted a study to estimate the incidence rate and predictors of fatigue after SARS-CoV-2 infection. The study reveals the long-term consequences of COVID-19, commonly known as long-COVID.
Read more »
Elusive immune cells dwelling in 'hidden niches' of the bone marrow may be key to SARS-CoV-2 vaccinationAlthough immunologists have developed a deep reservoir of knowledge illuminating how antibodies respond to vaccination against SARS-CoV-2, little is known about the elusive cells that produce infection-fighting antibodies.
Read more »
Survey of US adults reveals common cognitive symptoms in post-COVID-19 patients, linked to impaired daily functioning and depressionScientists examined how prevalent self-reported cognitive symptoms were in individuals with post-COVID-19 condition as compared to individuals who had prior severe SARS-CoV-2 infections but had not developed post-COVID-19 condition.
Read more »
COVID-19 rapid tests still work against new variants—researchers keep 'testing the tests,' and they passBy September 2020, just six months after COVID-19 triggered shutdowns across the U.S., it was clear that SARS-CoV-2, the virus that causes COVID-19, had mutated from its original form.
Read more »
Identifying antiviral protein IFN-γ as a potential biomarker for Long COVIDSARS-CoV-2 triggers the production of the antiviral protein IFN-γ, which is associated with fatigue, muscle ache and depression. New research shows that in Long COVID patients, IFN-y production persists until symptoms improve, highlighting a potential biomarker and a target for therapies.
Read more »
Iron dysregulation identified as potential trigger for long COVIDProblems with iron levels in the blood and the body's ability to regulate this important nutrient as a result of SARS-CoV-2 infection could be a key trigger for long COVID, new research has discovered.
Read more »